equitybuy

RGEN

Trust-weighted public proof page for RGEN. See which authors support it, which ticker theses it belongs to, and how thesis calls have performed.

Opportunity
99 / 100
Current score
1.74
Thesis calls
2
Active decisions
3

Recent proof-backed thesis calls

Public preview of asset-level thesis calls linked to source content, observed prices, and outcomes.

A Nature Aging paper (Steve Horvath) announces an open, searchable atlas of age-associated DNA methylation changes across 17 human tissues (>15,000 methylomes). Key implication: aging-related methylation change is directional/conserved (not just random drift) and variability increases across individuals. This is a positive signal for epigenetics/biomarker research but not an immediate company-specific catalyst.

Mentioned: Jul 1, 2026, 2:06 PM EDTConviction: 34 / 100
Source: Prof Steve Horvath @prof_horvath Jul 1 New in Nature Aging: an open, searchable atlas of how DNA methylation changes ...

Post claims a company has built a small cGMP cell therapy manufacturing facility and argues vertical integration of manufacturing is key for cell therapies; implies confidence/competence in GMP execution and potential strategic advantage for in-house manufacturing in cell therapy.

Mentioned: May 22, 2026, 11:59 AM EDTConviction: 50 / 100
Source: ^ I wish we had a more open comms policy but also: we built a small cGMP cell therapy manufacturing facility! Many co...

Current stance

Recommendationbuy
Authors2
Active decisions3
Latest pricen/a

Investment decisions

RGEN
research_buy

RGEN
research_buy

RGEN
research_buy

Unlock full asset monitoring

Create an account to inspect complete asset history, trust-weighted rankings, and persisted evidence across authors, theses, and market events.